108 related articles for article (PubMed ID: 12679736)
21. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
22. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
23. Merkel cell carcinoma: lack of KIT positivity and implications for the use of imatinib mesylate.
Yang Q; Hornick JL; Granter SR; Wang LC
Appl Immunohistochem Mol Morphol; 2009 Jul; 17(4):276-81. PubMed ID: 19276970
[TBL] [Abstract][Full Text] [Related]
24. Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117).
Fiorentini G; Rossi S; Lanzanova G; Bernardeschi P; Dentico P; De Giorgi U
Ann Oncol; 2003 May; 14(5):805. PubMed ID: 12702540
[No Abstract] [Full Text] [Related]
25. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
26. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
27. Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment.
Lugli A; Went P; Khanlari B; Nikolova Z; Dirnhofer S
Virchows Arch; 2004 Mar; 444(3):264-8. PubMed ID: 14677065
[TBL] [Abstract][Full Text] [Related]
28. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.
Roussidis AE; Theocharis AD; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2007; 14(7):735-43. PubMed ID: 17346159
[TBL] [Abstract][Full Text] [Related]
29. STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1.
Jin T; Nakatani H; Taguchi T; Nakano T; Okabayashi T; Sugimoto T; Kobayashi M; Araki K
World J Gastroenterol; 2006 Feb; 12(5):703-8. PubMed ID: 16521182
[TBL] [Abstract][Full Text] [Related]
30. C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib.
Castillo M; Petit A; Mellado B; Palacín A; Alcover JB; Mallofré C
J Urol; 2004 Jun; 171(6 Pt 1):2176-80. PubMed ID: 15126780
[TBL] [Abstract][Full Text] [Related]
31. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
32. p53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas.
Nio Y; Dong M; Uegaki K; Hirahara N; Minari Y; Sasaki S; Takamura M; Iguchi C; Tamura K
Anticancer Res; 1998; 18(5B):3773-9. PubMed ID: 9854494
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro.
Chung HW; Wen J; Lim JB; Bang S; Park SW; Song SY
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):862-9. PubMed ID: 19801102
[TBL] [Abstract][Full Text] [Related]
34. Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case.
Tsuneoka N; Kuroki T; Haraguchi M; Furui J
Surg Today; 2006; 36(11):989-93. PubMed ID: 17072721
[TBL] [Abstract][Full Text] [Related]
35. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.
Kamenz T; Caca K; Blüthner T; Tannapfel A; Mössner J; Wiedmann M
World J Gastroenterol; 2006 Mar; 12(10):1583-90. PubMed ID: 16570351
[TBL] [Abstract][Full Text] [Related]
36. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
39. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
40. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
